Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Alnylam PharmaceuticalsRoyalty PharmaCureVacCatalentOno Pharmaceutical
SymbolNASDAQ:ALNYNASDAQ:RPRXNASDAQ:CVACNYSE:CTLTOTCMKTS:OPHLF
Price Information
Current Price$138.31$42.12$102.61$109.91$25.05
52 Week RangeHoldHoldHoldBuyN/A
MarketRank™
Overall Score1.81.70.71.71.1
Analysis Score3.22.21.12.40.0
Community Score3.32.72.22.42.2
Dividend Score0.01.70.00.00.0
Ownership Score1.70.80.01.70.0
Earnings & Valuation Score0.61.30.01.93.1
Analyst Ratings
Consensus RecommendationHoldHoldHoldBuyN/A
Consensus Price Target$163.42$51.88$58.33$125.13N/A
% Upside from Price Target18.16% upside23.16% upside-43.15% downside13.84% upsideN/A
Trade Information
Market Cap$16.23 billion$25.57 billion$19.18 billion$18.71 billion$12.88 billion
Beta1.47N/AN/A1.51.06
Average Volume681,7423,106,983833,2951,068,531500
Sales & Book Value
Annual Revenue$219.75 millionN/AN/A$3.09 billion$2.69 billion
Price / Sales73.84N/AN/A6.054.79
CashflowN/AN/AN/A$3.57 per share$1.14 per share
Price / CashN/AN/AN/A30.8221.92
Book Value$12.90 per shareN/AN/A$18.71 per share$10.16 per share
Price / Book10.72N/AN/A5.872.47
Profitability
Net Income$-886,120,000.00N/AN/A$173 million$549.28 million
EPS($8.11)N/AN/A$1.88$1.09
Trailing P/E RatioN/A0.000.0070.0122.77
Forward P/E RatioN/A15.66N/A39.6815.37
P/E GrowthN/A1.94N/A2.68N/A
Net Margins-222.19%N/AN/A9.25%22.14%
Return on Equity (ROE)-65.96%N/AN/A14.20%11.29%
Return on Assets (ROA)-31.38%N/AN/A4.83%9.71%
Dividend
Annual PayoutN/A$0.68N/AN/AN/A
Dividend YieldN/A1.61%N/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/A1 YearsN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.59%N/A0.97%N/A
Current Ratio5.32%10.31%N/A2.56%2.78%
Quick Ratio5.18%10.31%N/A2.14%2.33%
Ownership Information
Institutional Ownership Percentage92.35%40.85%4.32%97.84%N/A
Insider Ownership Percentage3.50%2.50%N/A1.00%N/A
Miscellaneous
Employees1,453N/A50014,0003,560
Shares Outstanding117.32 million607.11 million186.91 million170.23 million514.12 million
Next Earnings Date5/5/2021 (Estimated)5/19/2021 (Estimated)N/A5/4/2021 (Estimated)5/11/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF) Sees Significant Increase in Short InterestOno Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF) Sees Significant Increase in Short Interest
americanbankingnews.com - April 2 at 1:08 AM
Pacira (PCRX) Gets FDA Nod for Exparel in Pediatric PatientsPacira (PCRX) Gets FDA Nod for Exparel in Pediatric Patients
msn.com - March 23 at 12:35 PM
Heres what to expect from Ono Pharmaceuticals earningsHere's what to expect from Ono Pharmaceutical's earnings
markets.businessinsider.com - January 31 at 5:58 PM
News for Ono PharmaceuticalNews for Ono Pharmaceutical
markets.businessinsider.com - December 26 at 8:08 PM
Fate Therapeutics Jumped On Supportive Trial DataFate Therapeutics Jumped On Supportive Trial Data
seekingalpha.com - December 18 at 8:10 AM
Gileads Cancer FolliesGilead's Cancer Follies
seekingalpha.com - October 2 at 7:58 AM
Ono Pharmaceutical Co., Ltd. (OPHLF)Ono Pharmaceutical Co., Ltd. (OPHLF)
ca.finance.yahoo.com - August 16 at 9:00 AM
Ono Pharmaceutical Co Ltd (Japan) (OPHLF)Ono Pharmaceutical Co Ltd (Japan) (OPHLF)
www.nasdaq.com - August 2 at 9:35 PM
Ono Pharmaceutical Co Ltd (Japan) (OPHLF) Short InterestOno Pharmaceutical Co Ltd (Japan) (OPHLF) Short Interest
www.nasdaq.com - September 28 at 2:49 AM
Japanese Nobel laureate Tasuku Honjo to sue Ono Pharmaceutical over cancer drug patent royaltiesJapanese Nobel laureate Tasuku Honjo to sue Ono Pharmaceutical over cancer drug patent royalties
www.japantimes.co.jp - July 28 at 11:14 AM
Ono Pharmaceutical to make Nobel laureate Tasuku Honjo new offer in bid to settle fee spat over OpdivoOno Pharmaceutical to make Nobel laureate Tasuku Honjo new offer in bid to settle fee spat over Opdivo
www.japantimes.co.jp - July 27 at 10:35 AM
Fate Therapeutics: Updates To Thesis, Gaining Momentum In The ClinicFate Therapeutics: Updates To Thesis, Gaining Momentum In The Clinic
seekingalpha.com - July 18 at 12:10 PM
Rafael Pharmaceuticals enters out-licensing agreement with Ono PharmaRafael Pharmaceuticals enters out-licensing agreement with Ono Pharma
njbiz.com - June 27 at 11:24 AM
Rafael Pharmaceuticals, Ono Pharmaceutical to accelerate clinical development of cancer drug candidate CPI-613Rafael Pharmaceuticals, Ono Pharmaceutical to accelerate clinical development of cancer drug candidate CPI-613
www.pharmaceutical-business-review.com - June 26 at 11:37 AM
Global Opdivo (Nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) Market Review & Forecast 2017-2026 - ResearchAndMarkets.comGlobal Opdivo (Nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) Market Review & Forecast 2017-2026 - ResearchAndMarkets.com
us.acrofan.com - June 24 at 5:33 PM
Cancer Research UK, LifeArc and Ono Pharma form cancer immunotherapy allianceCancer Research UK, LifeArc and Ono Pharma form cancer immunotherapy alliance
www.cancerresearchuk.org - March 27 at 12:46 PM
Vect-Horus enters into Collaboration and License Agreement with Ono Pharmaceutical Co., Ltd.Vect-Horus enters into Collaboration and License Agreement with Ono Pharmaceutical Co., Ltd.
www.marketwatch.com - March 26 at 12:21 PM
Ono Pharmaceutical and twoXAR Announce Drug Discovery Research CollaborationOno Pharmaceutical and twoXAR Announce Drug Discovery Research Collaboration
www.businesswire.com - March 18 at 11:17 AM
DateCompanyBrokerageAction
3/1/2021Alnylam PharmaceuticalsGuggenheimReiterated Rating
2/14/2021Alnylam PharmaceuticalsRoyal Bank of CanadaReiterated Rating
2/12/2021Alnylam PharmaceuticalsNeedham & Company LLCBoost Price Target
2/12/2021Alnylam PharmaceuticalsMorgan StanleyBoost Price Target
2/12/2021Alnylam PharmaceuticalsCitigroupDowngrade
2/12/2021Alnylam PharmaceuticalsBarclaysBoost Price Target
2/12/2021Alnylam PharmaceuticalsHC WainwrightBoost Price Target
1/25/2021Alnylam PharmaceuticalsBMO Capital MarketsDowngrade
1/13/2021Alnylam PharmaceuticalsCowenBoost Price Target
12/17/2020Alnylam PharmaceuticalsPiper SandlerBoost Price Target
11/24/2020Alnylam PharmaceuticalsSVB LeerinkBoost Price Target
10/15/2020Alnylam PharmaceuticalsBank of AmericaLower Price Target
10/12/2020Alnylam PharmaceuticalsChardan CapitalReiterated Rating
9/30/2020Alnylam PharmaceuticalsOppenheimerReiterated Rating
9/30/2020Alnylam PharmaceuticalsBerenberg BankInitiated Coverage
11/9/2020Royalty PharmaUBS GroupUpgrade
7/14/2020Royalty PharmaEvercore ISIInitiated Coverage
7/13/2020Royalty PharmaSunTrust BanksInitiated Coverage
7/13/2020Royalty PharmaJPMorgan Chase & Co.Initiated Coverage
7/12/2020Royalty PharmaThe Goldman Sachs GroupInitiated Coverage
12/10/2020CureVacCredit Suisse GroupDowngrade
9/8/2020CureVacJefferies Financial GroupInitiated Coverage
3/2/2021CatalentArgusBoost Price Target
11/5/2020CatalentDeutsche Bank AktiengesellschaftBoost Price Target
11/4/2020CatalentRobert W. BairdBoost Price Target
(Data available from 4/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.